NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $103.24
  • Forecasted Upside: 33.88 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$77.11
▼ -0.16 (-0.21%)

This chart shows the closing price for BMRN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioMarin Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BMRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMRN

Analyst Price Target is $103.24
▲ +33.88% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $103.24, with a high forecast of $152.00 and a low forecast of $82.00. The average price target represents a 33.88% upside from the last price of $77.11.

This chart shows the closing price for BMRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 11 contributing investment analysts is to buy stock in BioMarin Pharmaceutical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 7 hold ratings
  • 0 sell ratings
3/25/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 9 hold ratings
  • 0 sell ratings
6/23/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 9 hold ratings
  • 0 sell ratings
9/21/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 9 hold ratings
  • 0 sell ratings
12/20/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 7 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/18/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2021SVB LeerinkReiterated RatingBuyLow
9/9/2021Stifel NicolausUpgradeHold ➝ Buy$86.00 ➝ $96.00High
9/7/2021Royal Bank of CanadaReiterated RatingHold$88.00High
9/7/2021WedbushReiterated RatingBuy$152.00High
8/30/2021WedbushBoost Price TargetOutperform$141.00 ➝ $152.00Low
7/29/2021WedbushReiterated RatingBuy$141.00Medium
7/29/2021Jefferies Financial GroupInitiated CoverageBuy$112.00Medium
7/29/2021Royal Bank of CanadaBoost Price TargetSector Perform$87.00 ➝ $88.00High
7/29/2021Piper SandlerBoost Price TargetOverweight$112.00 ➝ $119.00Medium
7/16/2021WedbushReiterated RatingBuy$141.00Medium
7/11/2021SVB LeerinkInitiated CoverageBuy$83.62Medium
7/2/2021SVB LeerinkReiterated RatingBuyHigh
6/29/2021WedbushReiterated RatingBuy$141.00Low
4/28/2021WedbushReiterated RatingBuy$139.00Low
4/26/2021Credit Suisse GroupInitiated CoverageOutperform$102.00Medium
4/19/2021Morgan StanleyLower Price TargetEqual Weight$85.00 ➝ $82.00Low
3/23/2021WedbushReiterated RatingOutperform$139.00Medium
3/1/2021Canaccord GenuityLower Price TargetBuy$95.00 ➝ $91.00Low
3/1/2021Evercore ISIUpgradeIn-Line ➝ Outperform$90.00 ➝ $100.00Low
3/1/2021Robert W. BairdReiterated RatingBuyLow
1/11/2021Robert W. BairdBoost Price TargetPositive ➝ Outperform$100.00 ➝ $110.00High
11/6/2020SVB LeerinkLower Price TargetOutperform$113.00 ➝ $108.00High
9/10/2020TruistLower Price Target$130.00 ➝ $125.00Low
9/10/2020WedbushReiterated RatingBuyHigh
8/21/2020Morgan StanleyLower Price TargetEqual Weight$125.00 ➝ $85.00Low
8/20/2020TruistLower Price Target$143.00 ➝ $130.00Low
8/20/2020OppenheimerLower Price Target$116.00 ➝ $88.00Low
8/20/2020Canaccord GenuityLower Price TargetBuy$119.00 ➝ $95.00Low
8/20/2020Jefferies Financial GroupLower Price TargetBuy$138.00 ➝ $118.00Medium
8/20/2020William BlairReiterated RatingOutperform ➝ Market PerformMedium
8/19/2020CitigroupDowngradeBuy ➝ Neutral$148.00 ➝ $86.00Medium
8/19/2020WedbushReiterated RatingBuy$136.00Medium
8/19/2020SVB LeerinkLower Price TargetOutperform$140.00 ➝ $113.00High
8/19/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$123.00 ➝ $92.00High
8/19/2020Stifel NicolausDowngradeBuy ➝ Hold$127.00 ➝ $100.00High
8/14/2020The Goldman Sachs GroupBoost Price Target$172.00 ➝ $218.00Low
8/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$94.00 ➝ $108.00Low
8/5/2020OppenheimerInitiated CoverageHold$116.00Low
8/5/2020WedbushReiterated RatingBuy$146.00Low
8/5/2020BarclaysBoost Price Target$125.00 ➝ $135.00Low
8/5/2020Piper SandlerBoost Price Target$120.00 ➝ $133.00Low
8/5/2020Credit Suisse GroupReiterated RatingBuy$128.00Medium
8/5/2020JPMorgan Chase & Co.Boost Price TargetOverweight$140.00 ➝ $156.00Low
8/5/2020SVB LeerinkBoost Price TargetOutperform$130.00 ➝ $140.00Low
7/28/2020JPMorgan Chase & Co.Reiterated RatingBuy$140.00Low
7/27/2020WedbushReiterated RatingBuy$145.00Low
7/24/2020Robert W. BairdBoost Price Target$125.00 ➝ $140.00Low
7/8/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$125.00Low
7/6/2020CitigroupBoost Price TargetBuy$105.00 ➝ $148.00Low
6/21/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
6/18/2020WedbushReiterated RatingBuy$145.00High
6/18/2020SunTrust BanksBoost Price Target$109.00 ➝ $143.00Low
6/18/2020OppenheimerBoost Price TargetPerformer$88.00 ➝ $95.00High
6/17/2020SunTrust BanksBoost Price TargetBuy$109.00 ➝ $143.00Medium
6/10/2020Bank of AmericaBoost Price TargetBuy$120.00 ➝ $130.00Low
6/5/2020BarclaysBoost Price Target$105.00 ➝ $125.00Medium
6/3/2020WedbushReiterated RatingBuy$145.00Medium
6/1/2020Credit Suisse GroupReiterated RatingBuy$128.00Low
5/10/2020CfraReiterated RatingBuy$115.00Low
5/8/2020Canaccord GenuityBoost Price Target$108.00 ➝ $119.00Low
5/7/2020Credit Suisse GroupReiterated RatingBuy$128.00High
5/1/2020WedbushReiterated RatingOutperform$145.00Low
5/1/2020William BlairReiterated RatingBuyLow
5/1/2020Canaccord GenuityReiterated RatingBuy$108.00High
4/30/2020SunTrust BanksLower Price TargetBuy$110.00 ➝ $109.00High
4/30/2020NomuraReiterated RatingHold$77.00High
4/30/2020Credit Suisse GroupLower Price TargetOutperform$131.00 ➝ $128.00High
4/30/2020OppenheimerReiterated RatingHold$88.00High
4/6/2020WedbushReiterated RatingBuy$164.00High
3/24/2020WedbushReiterated RatingOutperformHigh
3/3/2020Morgan StanleyBoost Price TargetOverweight$120.00 ➝ $125.00Low
3/2/2020Nomura SecuritiesReiterated RatingHold$77.00Medium
3/1/2020WedbushReiterated RatingBuy$164.00High
2/28/2020CitigroupBoost Price Target$95.00 ➝ $105.00Medium
2/28/2020BarclaysReiterated RatingBuy$100.00Medium
2/27/2020OppenheimerBoost Price Target$88.00 ➝ $80.00Medium
2/23/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
2/21/2020WedbushReiterated RatingOutperform$158.00 ➝ $175.00Low
1/27/2020BMO Capital MarketsInitiated CoverageMarket Perform$94.00Medium
1/24/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$111.00 ➝ $113.00Low
1/21/2020WedbushReiterated RatingBuy$158.00Low
1/2/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
12/23/2019WedbushReiterated RatingBuy$158.00N/A
12/17/2019WedbushReiterated RatingBuy$158.00Low
12/16/2019Cantor FitzgeraldReiterated RatingBuy$129.00Low
12/16/2019Royal Bank of CanadaReiterated RatingHold$111.00Low
12/16/2019CowenReiterated RatingBuy$150.00Medium
12/13/2019Robert W. BairdReiterated RatingBuy$120.00High
12/11/2019Bank of AmericaReiterated RatingBuy$90.00High
11/27/2019BarclaysUpgradeEqual Weight ➝ Overweight$86.00 ➝ $98.00Medium
11/22/2019WedbushReiterated RatingBuy$157.00Low
11/15/2019William BlairReiterated RatingBuyLow
11/12/2019SunTrust BanksInitiated CoverageBuy$110.00Medium
10/30/2019CitigroupReiterated RatingBuy$120.00 ➝ $95.00Low
10/28/2019Canaccord GenuityLower Price TargetBuy$117.00 ➝ $108.00Low
10/25/2019WedbushBoost Price TargetOutperform$128.00 ➝ $152.00Low
10/24/2019Nomura SecuritiesLower Price Target$93.00 ➝ $77.00Medium
10/24/2019BarclaysLower Price TargetEqual Weight$95.00 ➝ $86.00Medium
10/21/2019Cantor FitzgeraldSet Price TargetBuy$129.00High
10/16/2019Bank of AmericaInitiated CoverageBuy$90.00Low
9/26/2019WedbushSet Price TargetBuy$128.00High
9/13/2019Piper Jaffray CompaniesSet Price TargetBuy$120.00Medium
9/13/2019Stifel NicolausSet Price TargetBuy$108.00Medium
8/5/2019JPMorgan Chase & Co.Reiterated RatingBuy$133.00High
7/10/2019WedbushReiterated RatingOutperform$128.00Medium
6/19/2019WedbushReiterated RatingOutperform$128.00Low
6/2/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
5/28/2019WedbushReiterated RatingBuy$128.00Medium
5/23/2019CitigroupReiterated RatingBuy ➝ BuyLow
4/26/2019Robert W. BairdSet Price TargetBuy$120.00Low
4/26/2019WedbushBoost Price TargetOutperform ➝ Outperform$127.00 ➝ $128.00Low
4/26/2019Cantor FitzgeraldReiterated RatingBuy$131.00Low
4/9/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$110.00Low
4/2/2019Robert W. BairdSet Price TargetBuy$120.00Low
4/2/2019Cantor FitzgeraldReiterated RatingBuy$131.00Low
3/4/2019Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$131.00Medium
2/26/2019WedbushSet Price TargetBuy$127.00Low
2/25/2019SunTrust BanksLower Price TargetBuy$117.00Medium
2/24/2019BarclaysReiterated RatingHold$95.00High
2/22/2019OppenheimerLower Price Target$92.00 ➝ $81.00Medium
2/7/2019WedbushReiterated RatingOutperform$127.00Low
1/8/2019OppenheimerSet Price TargetHold$92.00Medium
1/7/2019CowenReiterated RatingBuyMedium
1/7/2019Cantor FitzgeraldReiterated RatingBuy$126.00Low
1/2/2019Raymond JamesDowngradeOutperform ➝ Market Perform$83.16Medium
12/17/2018GuggenheimInitiated CoverageNeutralHigh
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformMedium
12/13/2018OppenheimerInitiated CoverageHold$92.00Low
11/28/2018Cantor FitzgeraldSet Price TargetBuy$126.00Medium
11/14/2018WedbushSet Price TargetBuy$127.00Low
11/4/2018Cantor FitzgeraldReiterated RatingBuy$126.00Low
10/29/2018WedbushSet Price TargetBuy$127.00Medium
10/26/2018Raymond JamesBoost Price TargetOutperform ➝ Buy$113.00 ➝ $114.00Low
10/26/2018Cantor FitzgeraldSet Price TargetBuy$126.00Medium
10/23/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$113.00 ➝ $116.00Low
10/16/2018Jefferies Financial GroupBoost Price TargetFair Value ➝ Buy$125.00High
10/15/2018Cantor FitzgeraldSet Price TargetBuy$126.00High
10/7/2018Cantor FitzgeraldSet Price TargetBuy$126.00Medium
9/28/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$126.00Low
9/13/2018WedbushSet Price TargetBuy$120.00Low
8/9/2018CitigroupBoost Price TargetBuy ➝ Buy$108.00 ➝ $120.00Low
8/6/2018WedbushReiterated RatingOutperform ➝ Outperform$115.00 ➝ $120.00High
8/5/2018JPMorgan Chase & Co.Reiterated RatingBuy$135.00High
8/5/2018BarclaysReiterated RatingEqual Weight ➝ Hold$95.00 ➝ $98.00High
8/3/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$113.00 ➝ $115.00High
8/3/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$102.00 ➝ $109.00High
7/31/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$105.00 ➝ $113.00Medium
7/9/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$120.00 ➝ $122.00Low
6/20/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
5/31/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$127.00 ➝ $133.00Low
5/29/2018CitigroupBoost Price TargetBuy$108.00Low
5/25/2018WedbushBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $115.00Low
5/25/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$116.00 ➝ $120.00Low
5/25/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$101.00 ➝ $105.00High
5/16/2018Canaccord GenuityInitiated CoverageBuy$101.00Low
5/15/2018WedbushReiterated RatingOutperform$112.00Low
5/7/2018SVB LeerinkBoost Price TargetOutperform$132.00 ➝ $145.00Medium
4/30/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$112.00 ➝ $113.00High
4/30/2018WedbushLower Price TargetOutperform$112.00 ➝ $110.00Medium
4/30/2018Sanford C. BernsteinLower Price TargetMarket Perform$97.00 ➝ $92.00Medium
4/26/2018JPMorgan Chase & Co.Set Price TargetBuy$127.00Medium
3/29/2018Credit Suisse GroupReiterated RatingBuy$116.00Medium
3/12/2018WedbushReiterated RatingOutperform$110.00Medium
3/2/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$113.00 ➝ $116.00High
2/27/2018Royal Bank of CanadaReiterated RatingHold$94.00Medium
2/25/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
2/25/2018Credit Suisse GroupReiterated RatingBuy$113.00Low
2/23/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$115.00 ➝ $112.00Medium
2/23/2018Stifel NicolausLower Price TargetBuy ➝ Buy$105.00 ➝ $102.00High
2/23/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$142.00 ➝ $132.00High
2/23/2018BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$119.00 ➝ $125.00High
2/23/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy ➝ Buy$119.00 ➝ $124.00High
1/24/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Outperform$131.00 ➝ $129.00Medium
1/18/2018Piper Jaffray CompaniesReiterated RatingBuy$114.00Low
1/18/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$113.00Low
12/22/2017WedbushReiterated RatingOutperform$110.00Medium
12/15/2017The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyHigh
12/14/2017WedbushUpgradeNeutral ➝ Outperform$110.00Low
12/11/2017SunTrust BanksBoost Price TargetBuy$130.00High
11/27/2017JPMorgan Chase & Co.Set Price TargetBuy$131.00Medium
11/15/2017WedbushReiterated RatingNeutral$108.00N/A
10/29/2017JPMorgan Chase & Co.Set Price TargetBuy$130.00N/A
10/27/2017BMO Capital MarketsBoost Price TargetOutperform$117.00 ➝ $119.00N/A
10/27/2017Stifel NicolausLower Price TargetBuy$107.00 ➝ $105.00N/A
10/20/2017BMO Capital MarketsReiterated RatingBuy$117.00N/A
10/19/2017SunTrust BanksSet Price TargetBuy$115.00N/A
10/19/2017SVB LeerinkReiterated RatingOutperform$136.00 ➝ $142.00N/A
10/19/2017Credit Suisse GroupReiterated RatingOutperform$114.00 ➝ $124.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$129.00N/A
10/6/2017Morgan StanleyReiterated RatingOverweight$115.00 ➝ $117.00N/A
9/26/2017Jefferies Financial GroupReiterated RatingBuy$116.00Low
9/21/2017Piper Jaffray CompaniesReiterated RatingBuy$113.00Medium
9/15/2017BMO Capital MarketsReiterated RatingBuyLow
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$93.00Medium
9/14/2017Piper Jaffray CompaniesInitiated CoverageNeutral ➝ Overweight$113.00Medium
8/31/2017CitigroupInitiated CoverageBuy ➝ Buy$98.00Medium
8/25/2017Jefferies Financial GroupSet Price TargetBuy$116.00Low
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$100.00High
8/9/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$118.00 ➝ $119.00Low
8/7/2017WedbushReiterated RatingNeutral$108.00High
8/4/2017Stifel NicolausReiterated RatingBuy$107.00Low
8/4/2017CowenReiterated RatingBuyLow
8/3/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$118.00 ➝ $119.00Low
8/3/2017UBS GroupReiterated RatingNeutral$92.00 ➝ $93.00Low
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$89.00High
7/22/2017BarclaysReiterated RatingEqual Weight$105.00 ➝ $100.00Low
7/18/2017SVB LeerinkReiterated RatingBuyLow
7/14/2017SunTrust BanksReiterated RatingBuy$115.00Low
7/13/2017BMO Capital MarketsReiterated RatingOutperform$111.00 ➝ $115.00Medium
7/11/2017CowenReiterated RatingBuyMedium
5/15/2017Jefferies Financial GroupReiterated RatingBuy$116.00N/A
5/15/2017CowenReiterated RatingBuy$150.00N/A
5/8/2017WedbushReiterated RatingHold$108.00Low
5/5/2017CowenReiterated RatingBuy$150.00Low
5/5/2017Jefferies Financial GroupReiterated RatingBuy$116.00High
5/1/2017JPMorgan Chase & Co.Reiterated RatingBuyMedium
4/28/2017Credit Suisse GroupReiterated RatingBuy$116.00Low
4/28/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$103.00 ➝ $105.00Low
4/26/2017Jefferies Financial GroupReiterated RatingBuy$116.00Medium
4/24/2017CowenReiterated RatingBuy$150.00Low
4/24/2017BMO Capital MarketsLower Price TargetOutperform$112.00 ➝ $105.00Low
4/18/2017Credit Suisse GroupReiterated RatingOutperform$112.00Low
4/18/2017CowenReiterated RatingOutperform$150.00Low
3/29/2017UBS GroupInitiated CoverageNeutral ➝ Neutral$92.00N/A
3/15/2017CowenReiterated RatingOutperform$150.00Low
3/8/2017CowenReiterated RatingOutperform$150.00Low
3/1/2017Nomura InstinetInitiated CoverageNeutral ➝ Neutral$93.00N/A
3/1/2017Nomura SecuritiesInitiated CoverageNeutralN/A
2/27/2017WedbushReiterated RatingNeutral$102.00N/A
2/25/2017JPMorgan Chase & Co.Set Price TargetBuy$123.00N/A
2/24/2017CowenReiterated RatingBuy$150.00N/A
2/10/2017GabelliReiterated RatingBuyN/A
2/8/2017WedbushReiterated RatingNeutral$102.00N/A
2/7/2017Morgan StanleyInitiated CoverageOverweight$110.00N/A
1/23/2017Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$111.00 ➝ $107.00N/A
1/9/2017Robert W. BairdSet Price TargetBuy$115.00N/A
12/25/2016GabelliInitiated CoverageBuyN/A
12/9/2016CowenSet Price TargetBuy$150.00N/A
12/8/2016GabelliInitiated CoverageBuy$109.00N/A
11/29/2016BarclaysDowngradeOverweight ➝ Equal Weight$125.00 ➝ $105.00N/A
11/7/2016Credit Suisse GroupReiterated RatingBuy$111.00N/A
11/7/2016Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$105.00 ➝ $84.00N/A
11/3/2016Deutsche Bank AktiengesellschaftInitiated CoverageBuy$106.00N/A
10/31/2016JPMorgan Chase & Co.Reiterated RatingBuy$127.00N/A
10/30/2016Royal Bank of CanadaSet Price TargetBuy$125.00N/A
10/28/2016WedbushReiterated RatingNeutral$102.00 ➝ $104.00N/A
10/15/2016Robert W. BairdSet Price TargetBuy$115.00N/A
10/14/2016Robert W. BairdReiterated RatingPositive$115.00N/A
10/13/2016SVB LeerinkReiterated RatingOutperform$127.00N/A
10/7/2016The Goldman Sachs GroupUpgradeNeutralN/A
9/16/2016SVB LeerinkReiterated RatingOutperform$127.00N/A
(Data available from 9/16/2016 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/18/2021
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/19/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/18/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/18/2021
  • 4 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/17/2021
  • 6 very positive mentions
  • 28 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
9/16/2021

Current Sentiment

  • 6 very positive mentions
  • 28 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

BioMarin Pharmaceutical logo
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
Read More

Today's Range

Now: $77.11
Low: $75.90
High: $77.29

50 Day Range

MA: $78.82
Low: $74.77
High: $85.15

52 Week Range

Now: $77.11
Low: $71.65
High: $92.57

Volume

12,125 shs

Average Volume

1,119,976 shs

Market Capitalization

$14.14 billion

P/E Ratio

17.97

Dividend Yield

N/A

Beta

0.53

Frequently Asked Questions

What sell-side analysts currently cover shares of BioMarin Pharmaceutical?

The following equities research analysts have issued research reports on BioMarin Pharmaceutical in the last twelve months: Canaccord Genuity, Credit Suisse Group AG, Evercore ISI, Jefferies Financial Group Inc., Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for BMRN.

What is the current price target for BioMarin Pharmaceutical?

11 Wall Street analysts have set twelve-month price targets for BioMarin Pharmaceutical in the last year. Their average twelve-month price target is $103.24, suggesting a possible upside of 33.6%. Wedbush has the highest price target set, predicting BMRN will reach $152.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $82.00 for BioMarin Pharmaceutical in the next year.
View the latest price targets for BMRN.

What is the current consensus analyst rating for BioMarin Pharmaceutical?

BioMarin Pharmaceutical currently has 2 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BMRN will outperform the market and that investors should add to their positions of BioMarin Pharmaceutical.
View the latest ratings for BMRN.

What other companies compete with BioMarin Pharmaceutical?

How do I contact BioMarin Pharmaceutical's investor relations team?

BioMarin Pharmaceutical's physical mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company's listed phone number is (415) 506-6700 and its investor relations email address is [email protected] The official website for BioMarin Pharmaceutical is www.bmrn.com.